ALTERNATIVE AGENT TO TAXANE ANTI-CANCER AGENT

摘要

Disclosed is an alternative agent to a taxane anti-cancer agent such as paclitaxel, which enables the extension of the withdrawal period for the taxane anti-cancer agent while maintaining the therapeutic effect of the taxane anti-cancer agent. The alternative agent comprises a p38MAPK inhibitor.  The alternative agent is administered to a patient who has a history of administration of the taxane anti-cancer agent at least two times over a period of 2 to 8 months for the purpose of potentiating an anti-cancer activity of the taxane anti-cancer agent and/or reducing adverse side effects of the taxane anti-cancer agent.  During the period of 2 to 8 months, the taxane anti-cancer agent is not administered to the patient.